Hypoglycaemic sulphonamides stimulate net uptake of 45Ca+ + and insulin release in isolated pancreatic islets. These effects are antagonized by organic calcium-antagonists (e.g. suloctidil). In an artificial system, hypoglycaemic sulphonamides, such as gliclazide, stimulate the translocation of calcium into or across a hydrophobic immiscible domain, a process enhanced by the antibiotic ionophore A 23187 and antagonized by suloctidil. In this artificial system, the A23187-mediated process of calcium countertransport is stimulated by gliclazide and inhibited by diazoxide. It is postulated that the insulinotropic action of hypoglycaemic and hyperglycaemic sulphonamides is primarily attributable to the ionophoretic action of these drugs.
Hypoglycaemic sulphonylureas stimulate insulin release from the pancreatic B-cell. The mechanism of such an insulinotropic effect is poorly understood [1] . Within the framework of current concepts concerning the cytophysiology of insulin release [2] , three primary sites of action could be proposed to account for the insulinotropic action of sulphonylureas: a facilitation of nutrient metabolism, an interference with cyclic AMP synthesis or breakdown, or a remodelling of ionic fluxes in the B-cell.
Biochemical studies, reviewed elsewhere [1, 3] , do not support the first of these 3 hypotheses.
Although hypoglycaemic sulphonylureas were occasionally claimed to activate adenylate cyclase [4] and repeatedly found to inhibit phosphodiesterase [5] [6] [7] in islet homogenates, the relevance of the latter finding may be questioned since sulphonylureas apparently do not penetrate the B-cell beyond the plasma membrane [1] . A drug-induced increase in the cyclic AMP content of intact islets could be secondary to a cytosolic accumulation of Ca 2+ [8] .
The third hypothesis, namely that of a primary action of hypoglycaemic sulphonylureas upon ionic movements, may involve two distinct mechanisms. First, sulphonylureas may cause a decrease in K § conductance [9, 10] leading to subsequent cell depolarization and gating of voltage-dependent Ca 2+ channels; however, under suitable conditions, tolbutamide is able to stimulate Ca 2+ influx and insulin release without decreasing K + conductance [11] . Second, sulphonylureas may directly interfere with an ionophoretic modality of Ca transport across the B-cell plasma membrane [12] [13] [14] [15] . This hypothesis has recently been scrutinized in great detail [16] [17] [18] .
The present report documents some selected experimental findings in support of the ionophoretic hypothesis.
Methodological Considerations
Insulin release was measured in groups of 8 pancreatic islets, removed from fed female albino rats and incubated for 60 min at 37~ in a bicarbonate-buffered solution [19] . The net uptake of 45Ca 2+ by the islets was measured over 90 min incubation, followed by repeated washes of the islets in order to remove extracellular radioactivity [20] .
Two methods were used to characterize the ionophoretic capacity of sulphonylureas and other drugs. In the first method, a small volume (0.2 ml) of a Hepes-NaOH buffer (25 mmol/1; pH 7.0) containing Na + 125, K + 5 and CI-120 mmol/1 and 45Ca 0012-186X/80/0019/0335/$01.20 The initial organic phase consisted of a toluene/butanol mixture (7/3, v/v). Gliclazide was added to the aqueous phase and A23187 to the organic phase, at the stated concentration. The Ca concentration of the final organic phase is shown as a function of the concentration of gliclazide. The slope of the regression line (b) was much higher (P < 0.001) in the presence of A23187 (upper line) than in its absence (lower line). Note the change in both elevation and relative scale of the 2 segments of the ordinate axis (1-10 gmol/1) was vigorously mixed for i rain at room temperature with an equal volume of a mixture of toluene/butanol (7/3, v/v). An aliquot (0.1 ml) of the supernatant immiscible organic phase was then examined for its readioactive content by liquid scintillation [21] . In the second method [22] , 0.15 ml of an organic mixture (toluene/butanol, 7/3, v/v) containing A 23187 (0.1 mmol/1) and, as required, gliclazide (16 mmol/1) or diazoxide (22mmol/1) was transferred back and forth between two tubes each containing 0.30 ml of aqueous medium and 0.05 ml of the same organic mixture. The two aqueous media consisted of a triethanolamine-HC1 buffer (20 mmol/ 1; pH7.0) containing 0.2 mmol/1 CaC12 (4~ and 45Ca) and either 2 or 200 mmol/1 LiC1. After each transfer, the aqueous medium and organic phase were vigorously mixed for 1 rain. Samples were removed from the aqueous media after each two back-and-forth transfers of the organic phase, and examined for their radioactive content. In these experiments, a Li + gradient was used because A23187 is able to mediate Li-Ca but not Na-Ca countertransport [22] .
All results are expressed as the mean ( + SEM) together with the number of individual observations. The statistical significance of differences between mean values was estimated by use of Student's t test. Figure 1 illustrates that gliclazide, like other hypoglycaemic sulphonylureas [3, 23] , stimulates 4SCa net uptake and insulin release from isolated islets. The time course [3, 23] and dose-action relationship [24] for the sulphonylurea-induced increase in 45Ca net uptake, as well as its modulation by the ambient concentration of glucose, coincide with the time course and magnitude of the drug-induced increment in insulin release.
Stimulation by Hypoglycaemic Sulphonylureas of Ca Entry and Net Uptake in Isolated Islets
The capacity of hypoglycaemic sulphonylureas to stimulate Ca entry into the islet cells is documented by the observation that these agents provoke a dramatic and immediate increase in 45Ca efflux from prelabelled islets and also by the abolition of this effect in the absence of extracellular Ca 2+ [25] , indicating that it corresponds to a process of Ca-Ca exchange between the influent 4~ and effluent 45Ca [26] . The mechanism by which hypoglycaemic sulphonylureas stimulate Ca influx into the islet cells is the major theme of the present work.
Ionophoretic Effects of Hypoglycaemic Sulphonylureas
As illustrated in Figure 2 , gliclazide is able to translocare Ca 2+ from an aqueous solution into an organic phase chosen to mimic the hydrophobic domain of the plasma membrane. Further studies reported in detail elsewhere [16] allowed us to characterize the ionophoretic effect of hypoglycaemic sulphonylureas as follows. Over a much wider range of concentrations than that used in Figure 2 , the amount of Ca 2+ translocated into the organic phase was proportional to the square of the drug concentration, suggesting a 2/1 stoichiometry for the interaction between Ca 2+ and the sulphonylureas. At increasing concentrations of Ca 2+ in the initial aqueous phase, the phenomenon of Ca 2+ translocation appeared as a saturable phenomenon. It was inhibited in a dose-related fashion by increasing concentrations of Na + or H +. Tolbutamide and gliclazide also provoked Na + translocation into the organic phase, the amount of Na + translocated being proportional to the drug concentration [16] .
All hypoglycaemic sulphonamides examined for such a purpose (i.e., tolbutamide, glycodiazin, gliclazide, glisoxepide, glipizide and glibenclamide) were able to translocate Ca 2+, whereas nonhypoglycaemic derivatives of either gliclazide or glipizide were unable to do so. Hypoglycaemic sulphonylurea s were also able to provoke the translocation of 45Ca from one aqueous medium into another across the organic mixture [16] . The concentrations of sulphonylureas used in these experiments were not higher than those presumed to be found in the phospholipid domain of the B-cell plasma membrane when pancreatic islets are exposed to the same extracellular concentration of the drug as that used in most in vitro studies, this estimation taking into account the reported values for the uptake of hypoglycaemic sulphonylureas by isolated islets [1] .
Combined Effect of Hypoglycaemic Sulphonylureas and Antibiotic Ionophores
The effect of hypoglycaemic sulphonylureas in causing Ca translocation into the organic phase is relatively modest at near-physiological Ca 2+ concentration in the aqueous phase [16] . This is due to a relatively low affinity of hypoglycaemic sulphonylureas, so that saturation of their ionophoretic capacity (i.e. translocation of one Ca atom for each two molecules of drug present in the organic phase) requires much higher Ca 2+ concentrations [16] .
The gliclazide-induced increment in Ca translocation is dramatically enhanced when the drug is used in combination with the antibiotic ionophore A 23187 (Fig. 2) . Such a cooperativity between distinct ionophoretic molecules, which is not an exceptional phenomenon [27] , represents an important feature of the present hypothesis. Indeed, the sulphonylureas may be better able to affect Ca transport across membrane systems in the B-cell when acting in synergism with native ionophores [28] . Moreover, when hypoglycaemic sulphonylureas and other ionophoretic molecules (e.g., A23187 or X537A) are used in combination, the transport of divalent cations is affected preferentially relative to that of monovalent cations. For instance, the combined use of X537A and gliclazide, which are both able to translocate Na and Ca into the organic phase when used separately, results in a synergistic effect upon the translocation of Ca, but not that of Na [17] . This dissociated behaviour is not surprizing, since the translocation of Na, as distinct from that of Ca, corresponds to a 1/1 stoichiometry for the interaction between Na and either X537A or gliclazide [16, 29] .
Inhibition by Organic Calcium-Antagonists of Gliclazide's Action
Organic calcium-antagonists such as verapamil, D 600, nifedipine and suloctidil inhibit insulin release evoked by a variety of secretagogues such as glucose, a-ketoisocaproate, Ba z+ and extracellular Ca 2+ in high concentrations [30] [31] [32] [33] [34] [35] [36] . The primary mode of action of the calcium-antagonists is to inhibit Ca 2+ entry into the islet cells [37] . The finding that verapamil also abolishes A23187-induced insulin release led us to postulate that the organic antagonist interacts with a Ca 2+ -binding site common to both A23187 and the native ionophore, located at the Bcell membrane [38] . The latter concept was indeed validated, in the artificial system, using either A23187 [39] or native ionophoretic material extracted from isolated islets [28] . Further analogies between the artificial system and intact cells include a competitive protective effect of Ca 2+ itself against the inhibitory action of verapamil [40] and the existence of a significant rank correlation between the relative efficiency of chemically-related drugs to inhibit Ca translocation into the organic phase and Ca 2+ -dependent biological processes, respectively [41] .
With this knowledge in mind, the fact that organic calcium-antagonists also inhibit 45Ca net uptake and insulin release evoked by hypoglycaemic sulphonylureas in isolated islets [37, 42] is not surprising and, at first glance, does not throw much light on the mode of action of the hypoglycaemic agents. However, the finding illustrated in Figure 1 that suloctidil, in addition to inhibiting 45Ca net uptake and insulin release in the islets, also inhibits gliclazide-mediated Ca translocation in the artificial system reveals a direct interference of the organic calcium-antagonist with the ionophoretic effect of gliclazide. Such a direct interference may explain why organic calciumantagonists, at a given concentration, are better able to inhibit 4SCa net uptake in islets exposed to hypoglycaemic sulphonylureas than in islets stimulated with glucose [37, 42] .
Further experiments have indicated that the dose-action relationship for the inhibitory effect of suloctidil upon gliclazide-or tolbutamide-mediated Ca translocation displays the same features as those found with other ionophores [16] , e.g., A23187. This similarity is important, since the dose-action relationship, when examined at various Ca 2+ concentrations, allows the demonstration of competition between Ca 2+ and its antagonist for a common site on the ionophoretic molecule [41] .
Opposite Effects of Hypoglycaemic and Hyperglycaemic Sulphonamides upon Ionophore-mediated Calcium Transport
The data so far presented in this report refer to the ionophoretic capacity of hypoglycaemic sulphonylureas. The hyperglycaemic sulphonamide diazoxide, which inhibits 45Ca net uptake and insulin release in isolated islets [20] , exerts no major effect upon 45Ca translocation in the two phase-system, whether in the presence or absence of antibiotic ionophores [16, 17] . The capacity of diazoxide to translocate Ca across the organic phase in the three phase-system is also negligible compared to that of gliclazide or tolbutamide [16, 18] .
Opposite effects of hypoglycaemic and hyperglycaemic sulphonylureas, respectively, upon ionophore-mediated calcium transport were observed, when investigating the influence of these agents upon Na-Ca or Li-Ca countertransport. In this countertransport process, Ca 2+ is transported by ionophores against its own chemical gradient and across the organic phase, provided that a suitable ion (Na +, Li +) is distributed asymmetrically, so that the downhill flux of Na + or Li + is coupled with the uphill transport of Ca 2+ in the opposite direction [22, 43] . Hypoglycaemic sulphonylureas are themselves able to mediate such a countertransport [18] . Diazoxide is unable to do so and does not affect sulphonylureamediated countertransport [18] . Gliclazide acts synergistically with A23187 in the process of countertransport, whereas diazoxide inhibits A23187- (Fig. 3) . When both sulphonamides are used in combination with A23187, the results are not significantly different from those seen when only gliclazide is present together with A23187 [18] . Comparable results were obtained when native ionophores extracted from the islets were used instead of A23 187 in this system [18] .
These data add considerable support to the ionophoretic hypothesis here under consideration. They indeed reveal that the well known opposite effects of hyperglycaemic and hypoglycaemic sulphonylureas, respectively, upon 45Ca net uptake [20, 23] , 45Ca efflux [25] and insulin release can be mimicked in the artificial system. Moreover, there are similarities with intact B-cells [44] where the inhibitory effect of diazoxide is suppressed and the stimulant action of gliclazide remains unaffected when both sulphonamides are used in combination.
Conclusion
The data presented in this report suggest that the ionophoretic capacity of hypoglycaemic and hyperglycaemic sulphonamides may play an important role in the expression of their insulinotropic action. Studies using more sophisticated models of artificial membranes are in progress in order to characterize further the influence of these drugs upon ion transport. Meanwhile, it is proposed that these drugs affect calcium movements in the B-cell, and possibly other organs (e.g. heart and platelets; see [45, 46] ), by interference with the process of calcium transport as mediated by native ionophores.
